Compare WULF & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WULF | KRYS |
|---|---|---|
| Founded | 1952 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.3B |
| IPO Year | 1995 | 2017 |
| Metric | WULF | KRYS |
|---|---|---|
| Price | $13.48 | $288.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | $17.58 | ★ $250.50 |
| AVG Volume (30 Days) | ★ 20.1M | 291.8K |
| Earning Date | 02-27-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 275.72 |
| EPS | N/A | ★ 6.66 |
| Revenue | $167,604,000.00 | ★ $373,164,000.00 |
| Revenue This Year | $29.95 | $36.14 |
| Revenue Next Year | $117.84 | $42.38 |
| P/E Ratio | ★ N/A | $43.40 |
| Revenue Growth | 30.58 | ★ 54.51 |
| 52 Week Low | $2.06 | $122.80 |
| 52 Week High | $17.05 | $295.98 |
| Indicator | WULF | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 67.40 |
| Support Level | $12.31 | $271.52 |
| Resistance Level | $14.55 | $295.98 |
| Average True Range (ATR) | 0.93 | 12.27 |
| MACD | 0.04 | 1.05 |
| Stochastic Oscillator | 57.84 | 83.20 |
TeraWulf Inc is a digital asset technology company that is engaged in digital infrastructure and sustainable energy development. It is involved in supporting environmentally conscious bitcoin mining operations by developing and operating facilities within the United States. The company's bitcoin mining facilities are powered by clean, affordable, and reliable energy sources. Its primary source of revenue stems from the mining of bitcoin conducted at the company's mining facility sites. Additionally, the company occasionally generates revenue through the provision of miner hosting services to third-party entities.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.